OrSense develops and commercializes non-invasive monitoring systems for oxygen saturation, hemoglobin, glucose, and other blood parameters. The company's flagship product is the CE approved NBM-200MP, a multi-parameter non-invasive, continuous blood oximetry and hemoglobin monitor for use in hospitals and outpatient sites. OrSense's CE approved glucose monitor was tested on over 450 diabetic subjects, showing performance similar to those of invasive glucose sensors. The company's products are based on its proprietary Occlusion Spectroscopy technology, which overcomes key obstacles that hinder the performance of other approaches. OrSense's devices were tested on 5,000 subjects, in over 40 clinical trials at 18 sites worldwide. Our products represent potential markets exceeding annual sales of $12B.  Investors in the company include Israel Health Care Ventures and STAR Ventures. Dr. Shimon Eckhouse is the chairman of the board.

Technology

OrSense's Occlusion Spectroscopy technology uses a ring-shaped sensor that is fitted on the finger and applies pressure, temporarily occluding the blood flow, during which, optical elements in the sensor measure the light transmitted through the finger. This provides a quick, accurate and painless measurement of blood constituents, improves patient comfort, eliminates infection risk, and provides superior accuracy and immediate results.

Contact Details
Address: 5 Golda Meir St,
Weizmann Science Park,
P.O.Box 4052,
Nes Ziona 74140,
ISRAEL
Phone: +972-8-9465142
Fax: +972-8-9465502
Email: orsense@orsense            
Internet Site: www.orsense.com 

Exhibition Representative
Name: Lior Ma'ayan, CEO
Mobile: +972-50-7577750
E-mail: lior.maayan@orsense.com 

Category: Medical Devices